Type 1 diabetes

Effect of Verapamil on Pancreatic Beta Cell Function in Newly Diagnosed Pediatric Type 1 Diabetes: A Randomized Clinical Trial

JAMAPublished Randomised controlled trial

Primary result · Mean C-peptide AUCResult — go to the resultAdjusted between-group difference 0.14 pmol/mL 95% CI 0.01–0.27

Authors' conclusion

In children and adolescents with newly diagnosed type 1 diabetes, verapamil partially preserved stimulated C-peptide secretion at 52 weeks from diagnosis compared with placebo. Further studies are needed to determine the longitudinal durability of C-peptide improvement and the optimal length of therapy.

Study context

Population
Children and adolescents aged 7 to 17 years with newly diagnosed T1D weighing ≥30 kg, 6 US centers; mean age 12.7 (SD 2.4) years, 41% female83 completed
Participants
88 children
Comparison
Once-daily oral verapamil vs placebo
  • Verapamiln = 47
  • Placebon = 41reference
Primary endpoint
Area under the curve values for C-peptide level stimulated by a mixed-meal tolerance test
Follow-up
52 weeks from diagnosis
Methodological detailsdouble-blind, factorial, multicentre
  • Double-blind
  • Factorial
  • Multicentre

Primary result

Mean C-peptide AUC · 52 weeks

Adjusted between-group difference

0.14 pmol/mL

95% CI 0.01–0.27

P = 0.04

By group

Verapamilvs Placebo
adjusted between-group difference 0.14 pmol/mL (95% CI 0.01–0.27); P = 0.04

As reported in the abstract

Higher C-peptide level at 52 weeks with verapamil
30%

Further findings

Mean C-peptide AUC at baseline

Peak C-peptide ≥0.2 pmol/mL · 52 weeks

%

OutcomeVerapamilPlaceboAdjusted between-group difference (%) (95% CI)
HbA1c · 52 weeks6.66.9−0.3 (−1.0% to 0.4%)
  • Peak C-peptide ≥0.2 pmol/mL: 41 of 43 vs 27 of 38 participants

Safety

Nonserious treatment-related adverse event

Original publication

Effect of Verapamil on Pancreatic Beta Cell Function in Newly Diagnosed Pediatric Type 1 Diabetes: A Randomized Clinical Trial. JAMA. Published 28 March 2023. doi:10.1001/jama.2023.2064

Composed by AI from the published abstract and checked against it. How Briefs are made →

Get them every week

New studies on this topic in My Week and in your Monday e-mail.

We e-mail you a sign-in link and a code. No password, no spam.